About Alpha/beta hydrolase domain-containing protein 17A
Alpha/beta hydrolase domain-containing protein 17A (ABHD17A) is a protein
from Homo sapiens identified by UniProt accession
Q96GS6, 310 residues long.
MolForge cross-references it against 0 known binders and
33 disease associations.
Target properties
| Protein name | Alpha/beta hydrolase domain-containing protein 17A |
|---|
| UniProt accession | Q96GS6 |
|---|
| Gene | ABHD17A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 310 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (33)
Diseases linked to this target (Open Targets).
- body fat percentage · score 0.11
- MODY · score 0.11
- body mass index · score 0.09
- type 2 diabetes mellitus · score 0.09
- body weight · score 0.07
- type 1 diabetes mellitus · score 0.07
- diabetes mellitus, transient neonatal, 2 · score 0.07
- reticulocyte count · score 0.07
- Red cell distribution width · score 0.06
- lean body mass · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96GS6-F1 | alphafold | PREDICTED | 88.87 | — |
Amino-acid sequence (310 residues)
MNGLSLSELC CLFCCPPCPG RIAAKLAFLP PEATYSLVPE PEPGPGGAGA APLGTLRASS GAPGRWKLHL TERADFQYSQ RELDTIEVFP TKSARGNRVS CMYVRCVPGA RYTVLFSHGN AVDLGQMSSF YIGLGSRLHC NIFSYDYSGY GASSGRPSER NLYADIDAAW QALRTRYGIS PDSIILYGQS IGTVPTVDLA SRYECAAVVL HSPLTSGMRV AFPDTKKTYC FDAFPNIEKV SKITSPVLII HGTEDEVIDF SHGLALYERC PKAVEPLWVE GAGHNDIELY SQYLERLRRF ISQELPSQRA
Explore Alpha/beta hydrolase domain-containing protein 17A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets